AnaptysBio Statistics

Total Valuation

AnaptysBio has a market cap or net worth of GBP 588.77 million. The enterprise value is 593.25 million.

Market Cap	588.77M
Enterprise Value	593.25M

Important Dates

The next estimated earnings date is Tuesday, August 5, 2025.

Earnings Date	Aug 5, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	29.38M
Shares Outstanding	n/a
Shares Change (YoY)	+10.16%
Shares Change (QoQ)	+0.64%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	17.61M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	6.80
PB Ratio	22.36
P/TBV Ratio	22.36
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-5.45
EV / Sales	7.13
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-7.02

Financial Position

The company has a current ratio of 8.25, with a Debt / Equity ratio of 10.17.

Current Ratio	8.25
Quick Ratio	8.13
Debt / Equity	10.17
Debt / EBITDA	n/a
Debt / FCF	-3.17
Interest Coverage	-1.62

Financial Efficiency

Return on equity (ROE) is -343.83% and return on invested capital (ROIC) is -16.60%.

Return on Equity (ROE)	-343.83%
Return on Assets (ROA)	-15.14%
Return on Invested Capital (ROIC)	-16.60%
Return on Capital Employed (ROCE)	-26.53%
Revenue Per Employee	636,675
Profits Per Employee	-800,306
Employee Count	136
Asset Turnover	0.27
Inventory Turnover	n/a

Taxes

In the past 12 months, AnaptysBio has paid 36,378 in taxes.

Income Tax	36,378
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -14.51% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-14.51%
50-Day Moving Average	22.19
200-Day Moving Average	21.31
Relative Strength Index (RSI)	67.32
Average Volume (20 Days)	225

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	15.45

Income Statement

In the last 12 months, AnaptysBio had revenue of GBP 86.59 million and -108.84 million in losses. Loss per share was -3.71.

Revenue	86.59M
Gross Profit	-43.43M
Operating Income	-77.62M
Pretax Income	-108.81M
Net Income	-108.84M
EBITDA	-77.17M
EBIT	-77.62M
Loss Per Share	-3.71

Full Income Statement

Balance Sheet

The company has 263.11 million in cash and 267.77 million in debt, giving a net cash position of -4.66 million.

Cash & Cash Equivalents	263.11M
Total Debt	267.77M
Net Cash	-4.66M
Net Cash Per Share	n/a
Equity (Book Value)	26.33M
Book Value Per Share	0.87
Working Capital	246.96M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -84.20 million and capital expenditures -283,280, giving a free cash flow of -84.48 million.

Operating Cash Flow	-84.20M
Capital Expenditures	-283,280
Free Cash Flow	-84.48M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is -50.15%, with operating and profit margins of -89.64% and -125.70%.

Gross Margin	-50.15%
Operating Margin	-89.64%
Pretax Margin	-125.66%
Profit Margin	-125.70%
EBITDA Margin	-89.12%
EBIT Margin	-89.64%
FCF Margin	n/a

Dividends & Yields

AnaptysBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.16%
Shareholder Yield	n/a
Earnings Yield	-18.49%
FCF Yield	-14.35%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AnaptysBio has an Altman Z-Score of -1.15 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.15
Piotroski F-Score	3